Novel Electrochemiluminescence Immunoassay Exclusively for Full-length Parathyroid Hormone during Treatment with Cinacalcet for Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 15, Issue SUPPL.1, 2011, Pages 56-61

  Tanaka, Hisae ^a   Komaba, Hirotaka ^a,b   Koizumi, Masahiro ^a,b   Kakuta, Takatoshi ^a   Fukagawa, Masafumi ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cinacalcet hydrochloride; Electrochemiluminescence immunoassay; Intact parathyroid hormone; Parathyroid hormone (1 84); Secondary hyperparathyroidism

Indexed keywords

CALCIUM CARBONATE; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; REGPARA; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; DRUG EFFECT; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

AGED; CHEMILUMINESCENT MEASUREMENTS; ELECTROCHEMISTRY; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 79956208102     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00928.x     Document Type: Article

References (32)

1. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-52.
2. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70(Suppl 102):S3-7.
3. Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone 2009;44:666-70.
4. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77:93-100.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-S130.
6. Brossard JH, Cloutier M, Roy L etal. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9.
7. Brossard JH, Lepage R, Cardinal H etal. Influence of glomerular filtration rate on intact parathyroid hormone levels in renal failure patients: role of non-(1-84) PTH detected by intact PTH assays. Clin Chem 2000;46:697-703.
8. John MR, Goodman WG, Gao P etal. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
9. Komaba H, Nakanishi S, Fujimori A etal. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010;5:2305-14.
10. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-25.
11. Payne RB, Little AJ, Williams RB etal. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973;4:643-6.
12. Souberbielle JC, Boutten A, Carlier MC etal. Intermethod variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-50.
13. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int 2006;70(Suppl 102):S29-S33.
14. Gao P, Scheibel S, D'Amour P etal. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone (1-84): implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
15. Nakanishi S, Kazama JJ, Shigematsu T etal. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001;38(Suppl 1):S172-S174.
16. Inaba M, Okuno S, Imanishi Y etal. Significance of Bio-intact PTH (1-84) assay in hemodialysis patients. Osteoporosis Int 2005;16:517-25.
17. Block GA, Martin KJ, de Francisco ALM etal. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
18. Fukagawa M, Yumita S, Akizawa T etal. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23:328-35.
19. Kawata T, Imanishi Y, Kobayashi K etal. Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells. J Clin Endocrinol Metab 2005;90:5774-8.
20. Martin KJ, Jüppner H, Sherrard DJ etal. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005;68:1236-43.
21. Kurajoh M, Inaba M, Okuno S etal. Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. Osteoporos Int 2011;22:923-30.
22. Valle C, Rodriguez M, Santamaría R etal. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 2008;19:2430-6.
23. Komaba H, Shin J, Fukagawa M. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. Nephrol Dial Transplant 2010;25:638-41.
24. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037-44.
25. Arakawa T, D'Amour P, Rousseau L etal. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol 2006;1:525-31.
26. Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M. Normalization of reversed bio-intact-PTH (1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol 2005;64:69-72.
27. Komaba H, Takeda Y, Abe T etal. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant 2008;23:1760-2.
28. Komaba H, Takeda Y, Shin J etal. Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. NDT Plus 2008;1(Suppl 3):iii54-iii58.
29. Komaba H, Fukagawa M. Amino-terminal form of parathyroid hormone in CKD. Kidney Int 2010;78:110-1.
30. Monier-Faugere MC, Geng ZP, Mawad H etal. Improved assessment of bone turnover by the PTH-(1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:1460-8.
31. Coen G, Bonucci E, Ballanti P etal. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002;40:348-54.
32. Lehmann G, Stein G, Huller M etal. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005;68:1206-14.